EU Novel Food Regulation and CBD Products

The European Union's Novel Food Regulation (EU 2015/2283) has become one of the most consequential pieces of legislation affecting the CBD industry in Europe. Under this framework, CBD extracts and synthesized cannabidiol are classified as novel foods, meaning they require pre-market authorization before they can be legally sold as food supplements or ingredients within EU member states. This classification has created significant barriers to entry for CBD companies and reshaped the competitive landscape across the European market. The novel food authorization process is rigorous, requiring applicants to submit comprehensive safety dossiers that include toxicological studies, stability data, proposed specifications, and evidence of a history of safe use. The European Food Safety Authority (EFSA) evaluates each application, a process that typically takes 18 months or longer. As of early 2026, several applications remain under review, while the market continues to operate in a regulatory grey zone where enforcement varies dramatically between member states. Companies selling CBD products in Europe without novel food authorization face increasing regulatory risk as enforcement mechanisms mature.

The origins of the novel food classification for CBD trace back to January 2019, when the European Commission updated its Novel Food Catalogue to explicitly list cannabinoids including CBD as novel. This decision was based on the determination that CBD extracts derived from Cannabis sativa had no significant history of consumption as food within the EU prior to May 1997, the cut-off date established under the regulation. The classification triggered immediate disruption across the European CBD market, as hundreds of products that had been freely sold suddenly required authorization that no company yet possessed. Industry groups challenged the classification, arguing that hemp-derived products have centuries of traditional use in Europe, but the Commission maintained its position that isolated or enriched CBD extracts represent a fundamentally different product from historical hemp food use.

The authorization process itself presents substantial challenges for CBD companies. A complete novel food application must include detailed manufacturing process descriptions, compositional data, proposed product specifications, toxicological safety assessments (often requiring 90-day oral toxicity studies in animals), and evidence of stability under normal storage conditions. The cost of preparing a compliant application typically ranges from 300,000 to 500,000 euros, placing it beyond the reach of many small and medium-sized CBD enterprises. EFSA has also raised specific safety concerns around CBD, including potential interactions with medications, effects on the liver at high doses, and reproductive toxicity — issues that applicants must address with robust scientific data. The timeline from application submission to a Commission decision typically spans 18-24 months, during which the applicant has no certainty of approval.

Enforcement of the novel food requirement varies significantly across EU member states, creating a patchwork regulatory environment. Countries like Belgium, Denmark, and Sweden have taken aggressive enforcement positions, removing non-authorized CBD products from shelves and issuing warnings to retailers. Others, including the Netherlands and Czech Republic, have adopted a more permissive stance, allowing CBD products to remain on the market pending the outcome of novel food applications. This inconsistency creates competitive distortions and regulatory arbitrage opportunities, with some companies strategically choosing to base operations in more lenient jurisdictions. The European Commission has acknowledged the enforcement gap but has largely left implementation to national authorities.

Looking ahead, the resolution of pending novel food applications will fundamentally shape the European CBD market. If authorizations are granted, they will establish clear quality and safety standards that legitimate operators can meet, while effectively barring non-compliant products. The first successful authorization will also set a precedent for specification limits, permitted health claims, and maximum daily intake levels that will define product formulation across the industry. Industry analysts project that a functioning novel food framework could expand the European CBD market from an estimated 2-3 billion euros in 2025 to 5-8 billion euros by 2030, as regulatory clarity attracts institutional investment and mainstream retail distribution. However, if the process stalls or results in overly restrictive conditions, the European market risks falling further behind North America in CBD innovation and consumer adoption.